Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicentric Randomized Study on Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients

NCT04976036 is registered in ClinicalTrials.gov with Dr. Romain Lazor as lead sponsor.

NCT NCT04976036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04976036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicentric Randomized Study on Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
Lead sponsor
Dr. Romain Lazor
Phase
Phase 2
Overall status
Recruiting
Start date
May 5, 2022
Completion date
December 31, 2026
Enrollment
48 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

telangiectasia, hereditary hemorrhagic